29.03.2017 • NewsElaine BurridgeExxonMobiljac

ExxonMobil Takes Jurong Aromatics

(c) Jurongaromatics
(c) Jurongaromatics

ExxonMobil has emerged as the winner for Singapore-based Jurong Aromatics Corp. (JAC), outbidding Lotte Chemical and Hanwha Total Petrochemicals, according to a report in The Korea Herald newspaper. The acquisition is expected to close in the first half of 2017.

The US oil and gas firm is said to have offered about 2 trillion won ($1.78 billion), which was double the respective 1 trillion won the South Korean firms reportedly bid.

According to media reports, Lotte Chemical said in a filing to the South Korean stock exchange that it had not been successful in acquiring JAC. The Seoul-headquartered company was shortlisted on Jan. 10 after submitting a letter of intent to acquire the debt-ridden aromatics group, which went into receivership in September 2015.

JAC, which produces around 1.5m t/y of aromatics, restarted operations last July after an 18-month shutdown.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.